Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit
News Feb 13, 2007
Regenetech Inc., the adult stem cell company which uses NASA-licensed technology, announces that at the Second Annual Stem Cell Summit, it makes its licenses available to stem cell banks for its cellXpansion™ technology, which expands hematopoietic stem cells for autologous use.
Dr. David Bonner, Chief Executive Officer of Regenetech, said: “We believe that the essential barrier to wide-spread medical use of adult stem cells is the lack of convenient and economical therapeutic doses of adult stem cells. We believe that Regenetech’s technology provides the most cost-effective solution to this problem. Through the use of our cellXpansion™ system, we hope to make adult stem cell therapy available on a widespread basis.”
In order to encourage broader use of its technology, Regenetech will also make available research licenses at nominal cost to not-for-profit institutions pursuing stem cell research.
Under license from NASA, Regenetech has extended NASA’s patented human progenitor cell technology for use in stem cell banking based on peripheral or umbilical cord blood sources of stem cells.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.